All people is one
The consortium consists of 18 organisations, covering all the necessary components of the ecosystem and of the innovation chain, to reach the project objectives.
12 clinical partners and a supporting CRO have been involved to perform the clinical study.
The clinical partners are:
- Fondazione Europea di Ricerca Biomedica, Gazzaniga (Italy) (PI: Carlo A. Defanti, co-PI: Sara Fascendini)
- Sykehuset Innlandet, Ottestad, Norway (PI: Sverre Bergh)
- Université de Genève, Switzerland (PI: Giovanni B Frisoni, Co-PI: Julius Popp)
- Azienda Unità Sanitaria Locale di Modena; Italy (PI: Andrea Fabbo)
- Zentralinstitut für Seelische Gesundheit, Mannheim, Germany (PI: Lutz Froelich)
- Azienda Socio Sanitaria Territoriale di Mantova, Italy (PI: Alfonso Ciccone)
- Charité – Universitätsmedizin Berlin, Germany (PI: Oliver Peters)
- Cliniche Gavazzeni SpA Bergamo, Italy (PI: Paola Merlo)
- Università degli Studi di Perugia, PG, Italy (PI: Patrizia Mecocci)
- Assistance Publique – Hopitaux de Paris, France (PI: Jacques Hugon)
- Aristotelio Panepistimio Thessalonikis, Greece (PI: Magda Tsolaki)
The CRO is: Mediolanum Cardioresearch, Milan, Italy (Maria C. Jori)
A health economist (Ron Handels, Maastricht University) will be in charge of the cost-effectiveness analysis.
Further to the above mentioned partners, two governmental organisations (Regione Emilia Romagna, Italy, and Athens Association of Alzheimer Disease and Related Disorders (AAADRD), have been involved from the two countries where the SCU-B is less widespread (Italy and Greece). Their role will be mainly to evaluate the model of SCU-B, to identify factors promoting and hindering the effectiveness of SCU-B by studying BPSD management for dementia in countries where it is established.
Two national patient associations have been selected, one from Italy (Federazione Alzheimer Italia) and one from Greece (Elliniki Etairia Nosoy Alzheimer Kai Syggenon Diatarachon Somateio), in order to have a representations from the countries where SCU-B is not widely present.
The main role of these associations will be to support the dissemination and communication processes, by raising public awareness about BPSD, about problems associated with early institutionalization and about the social importance of this condition.